Skip to main content

Alnylam gets FDA OK to restart hemophilia drug trial after patient's death

The Cambridge biotech says the FDA had lifted a clinical hold that was announced in September.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.